OSE2101 is a T-cell epitope-based cancer vaccine designed to induce cytotoxic T cells against five TAAs frequently overexpressed in NSCLC (HER-2/neu, CEA, MAGE 2, MAGE 3, and p53) [28]. This evidence concerns the gene ERBB2 and cancer.